Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment

Patients with Von Willebrand disease (VWD) are regularly treated with VWF‐containing concentrates in case of acute bleeding, trauma and dental or surgical procedures.

[1]  F. Leebeek,et al.  Current and Emerging Options for the Management of Inherited von Willebrand Disease , 2017, Drugs.

[2]  A. Atalar,et al.  Surgery in patients with von Willebrand disease , 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  G. Dolan,et al.  Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  F. Leebeek,et al.  Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications , 2016, Journal of thrombosis and haemostasis : JTH.

[5]  W. Miesbach,et al.  Interaction between VWF and FVIII in treating VWD , 2015, European journal of haematology.

[6]  V. Valderrábano,et al.  Total ankle replacement in patients with von Willebrand disease: mid‐term results of 18 procedures , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  E. Raquet,et al.  Utility of a high VWF:FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice , 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[8]  J. Eikenboom,et al.  von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. , 2015, Blood.

[9]  R. Tait,et al.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology , 2014, British journal of haematology.

[10]  P. Mannucci,et al.  Orthopaedic surgery in patients with von Willebrand disease , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  W. Hopman,et al.  Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  P. Kyrle,et al.  Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. , 2013, Blood transfusion = Trasfusione del sangue.

[13]  M. Morfini.  Pharmacokinetics of VWF/FVIII concentrates is a very intricate matter , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  L. Valentino,et al.  von Willebrand factor/factor VIII concentrate (Humate‐P) for management of elective surgery in adults and children with von Willebrand disease , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  P. Mannucci,et al.  Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand’s disease (VWD) has limited value in dosing for surgery , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  P. T. Onundarson,et al.  Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease. , 2011, Seminars in thrombosis and hemostasis.

[17]  G. Castaman.  Treatment of von Willebrand disease with FVIII/VWF concentrates. , 2011, Blood transfusion = Trasfusione del sangue.

[18]  O. Christophe,et al.  Factor VIII and von Willebrand factor – too sweet for their own good , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[20]  M. Franchini.  Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. , 2008, Blood transfusion = Trasfusione del sangue.

[21]  P. Mannucci,et al.  A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate®P/ Humate®‐P: History and clinical performance , 2008, European journal of haematology. Supplementum.

[22]  P. Mannucci,et al.  von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery , 2007, Journal of thrombosis and haemostasis : JTH.

[23]  P. Mannucci,et al.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor , 2006, Journal of thrombosis and haemostasis : JTH.

[24]  P. Mannucci,et al.  Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods , 2005, Journal of thrombosis and haemostasis : JTH.

[25]  P. Wells,et al.  Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada – is it necessary to define a new upper reference range for factor VIII? , 2005, Thrombosis and Haemostasis.

[26]  S. Lethagen,et al.  A comparative in vitro evaluation of six von Willebrand factor concentrates , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  J. Gill,et al.  Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate‐P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  G. Lippi,et al.  Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. , 2003, Haematologica.

[29]  M. Makris,et al.  Venous Thrombosis Following the Use of Intermediate Purity FVIII Concentrate to Treat Patients with Von Willebrand’s Disease , 2002, Thrombosis and Haemostasis.

[30]  P. Mannucci,et al.  Venous Thromboembolism in Von Willebrand Disease , 2002, Thrombosis and Haemostasis.

[31]  D. Lillicrap,et al.  Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease , 2002, Thrombosis and Haemostasis.

[32]  L. Sleeper,et al.  Surgery and Anesthesia in Sickle Cell Disease , 2002 .

[33]  S. Lethagen.  Haemostatic treatment in connection with surgery in patients with von Willebrand disease , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  Scott T. Miller,et al.  Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. , 1995, Blood.

[35]  F Rodeghiero,et al.  Epidemiological investigation of the prevalence of von Willebrand's disease. , 1987, Blood.